Zacks Investment Research Downgrades Aytu BioPharma (NASDAQ:AYTU) to Sell

Zacks Investment Research downgraded shares of Aytu BioPharma (NASDAQ:AYTUGet Rating) from a hold rating to a sell rating in a research note published on Thursday morning, Zacks.com reports.

According to Zacks, “Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. The company’s marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual dysfunction. Aytu BioScience, Inc. is based in Englewood, Colorado. “

AYTU has been the topic of a number of other reports. HC Wainwright lowered their price target on shares of Aytu BioPharma from $24.00 to $11.00 and set a buy rating on the stock in a research report on Thursday, April 28th. Cantor Fitzgerald lowered their price target on shares of Aytu BioPharma from $11.00 to $5.00 in a research report on Tuesday, May 17th.

Shares of AYTU opened at $0.56 on Thursday. The firm has a market capitalization of $18.75 million, a PE ratio of -0.14 and a beta of -0.13. The company’s 50-day moving average is $0.83 and its 200-day moving average is $1.29. Aytu BioPharma has a fifty-two week low of $0.45 and a fifty-two week high of $6.18. The company has a debt-to-equity ratio of 0.30, a current ratio of 0.97 and a quick ratio of 0.71.

Aytu BioPharma (NASDAQ:AYTUGet Rating) last released its quarterly earnings results on Monday, May 16th. The company reported ($1.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($1.38). Aytu BioPharma had a negative return on equity of 41.97% and a negative net margin of 120.24%. Analysts predict that Aytu BioPharma will post -2.58 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC grew its stake in Aytu BioPharma by 15.1% during the first quarter. Renaissance Technologies LLC now owns 765,469 shares of the company’s stock worth $827,000 after buying an additional 100,400 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Aytu BioPharma by 10.0% in the 4th quarter. BlackRock Inc. now owns 548,724 shares of the company’s stock valued at $741,000 after purchasing an additional 49,772 shares in the last quarter. Morgan Stanley boosted its stake in shares of Aytu BioPharma by 793.5% in the 3rd quarter. Morgan Stanley now owns 377,922 shares of the company’s stock valued at $1,088,000 after purchasing an additional 335,625 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Aytu BioPharma by 16.3% in the 3rd quarter. Geode Capital Management LLC now owns 257,433 shares of the company’s stock valued at $741,000 after purchasing an additional 35,994 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Aytu BioPharma in the 4th quarter valued at approximately $70,000. Hedge funds and other institutional investors own 11.47% of the company’s stock.

Aytu BioPharma Company Profile (Get Rating)

Aytu Biopharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older.

See Also

Get a free copy of the Zacks research report on Aytu BioPharma (AYTU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.